Biocatalyst for synthesizing ubrogepant intermediate and method for synthesizing same

Abstract

The present application provides an engineered aminotransferase polypeptide for synthesizing ubrogepant intermediates with high stereoselectivity, high catalytic activity, and excellent stability. The present application also provides a reaction process for the asymmetric synthesis of ubrogepant intermediates ((5S,6R)-6-methyl-2-oxo-5-phenyl-3-carbamic acid tert-butyl ester)piperidine using the aminotransferase polypeptide, and a purification process for the product.

Description

[Technical Field]

[0001] The present invention relates to the field of biotechnology, and in particular to the use of engineered aminotransferase polypeptides in catalyzing the synthesis of ubrogepant intermediates. [Background technology]

[0002] Migraine is a common primary headache syndrome characterized by a moderate to severe, throbbing headache, primarily on one side, which may be accompanied by nausea, vomiting, photophobia, and other symptoms. Currently, more than 10% of the world's population suffers from migraine, with women accounting for approximately twice as many as men. Migraine development has a complex genetic cause, but the genes involved in migraine development remain unclear, and the underlying mechanism of migraine pathogenesis has yet to be clearly elucidated. Traditionally, triptan drugs, such as sumatriptan, zolmitriptan, and almotriptan, which act on the 5HT1B / 1D receptor, have been used to treat migraine. However, due to their inherent vasoconstrictive effects, they are not suitable for use in migraine patients with underlying cardiovascular disease. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, has vasodilatory properties and can act at multiple sites. It can be involved in nociception and sensitization of peripheral and central neurons in the trigeminovascular system, which are related to the pathophysiology of migraine. CGRP receptor antagonism has now proven to be an effective method for alleviating migraines. Ubrogepant, approved for marketing by the FDA in 2019, is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for the treatment of migraines. Ubrogepant relieves migraine symptoms by blocking the binding of CGRP to its receptor. Its mechanism of action is completely different from that of conventional triptans, exerting its effects in a novel way without vasoconstriction, a problem with many existing migraine treatments.

[0003] In the paper "Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant" (Org. Process Res. Dev. 2017, 21, 1851-1858), Nobuyoshi Yasuda et al. disclosed a method for synthesizing ubrogepant (see Figure 1). Ubrogepant contains two core structural fragments: one is a lactam containing three chiral centers (represented by structural formula L2), and the other is a spiro acid (represented by structural formula A1), with the lactam being the most difficult to synthesize. To synthesize the key intermediate L2, Nobuyoshi Yasuda and colleagues first synthesized the compound represented by structural formula S1 (isopropyl 4-phenyl-2-(tert-butoxycarbonylamino)-5-oxohexanoate). Using S1 (theoretically containing four different isomers: ST1, ST2, SD1, and SD2), they performed dynamic kinetic catalysis with aminotransferase in 50% dimethyl sulfoxide (DMSO) to obtain lactam L1, in which two chiral centers are immobilized. This aminotransferase-catalyzed reaction utilizes substrate epimerization to prepare L1 in one step with high chiral purity. If the aminotransferase is active only toward the isomers ST1 and ST2 of the S1 substrate, but not toward SD1 or SD2, ST1 and ST2 can be converted by the aminotransferase to IT1 and IT2, respectively (the structural ester bonds of IT1 and IT2 spontaneously cleave, allowing subsequent ring formation to form L1). Therefore, ID1 and ID2 are not present in the product. Furthermore, under appropriate reaction conditions, once ST1 and ST2 are consumed, the isomers SD1 and SD2, which could not participate in the aminotransferase reaction, are spontaneously converted in situ to ST1 and ST2, and the resulting ST1 and ST2 are then converted to IT1 and IT2 by the aminotransferase. The key to this reaction is the need to develop an aminotransferase with extremely high selectivity for the ST1 and ST2 isomers of the substrate S1.Specifically, it is only active against ST1 and ST2, but not against SD1 and SD2. Conversion of the desired carbonyl to an amino produces only the R-configuration amino. This affords lactam L1 with extremely high chiral purity. In the aminotransferase reaction disclosed by Nobuyoshi Yasuda et al., the ratio of the sum of the concentrations of IT1 and IT2 to the sum of the concentrations of ID1 and ID2 in the product (i.e., the diastereomeric ratio, or dr) was up to 61:1. After obtaining intermediate L1 via the aminotransferase reaction, Nobuyoshi Yasuda et al. performed an alkylation reaction and induced diastereomeric conversion using crystallization to prepare L2.

[0004] JPEG0007764620000001.jpg60170

[0005] JPEG0007764620000002.jpg83170JPEG0007764620000003.jpg52170

[0006] The present invention discloses an engineered aminotransferase with superior performance suitable for the dynamic kinetic catalytic reaction of aminotransferases synthesizing L1 and its analogs. The engineered aminotransferase provided by the present invention has better tolerance to the solvent used in the reaction, better activity, and better thermostability. Furthermore, the present invention optimizes the aminotransferase reaction system and work-up system by using a mixed solvent of dimethyl sulfoxide (DMSO) and acetonitrile (ACN) as the reaction solvent, significantly improving the low solubility of the substrate S1 when DMSO alone is used. It also avoids the impact on enzyme activity caused by excessively high concentrations of acetonitrile, a single solvent with higher substrate solubility. Furthermore, it allows for partial recycling of the solvent in the work-up process, making it economical and environmentally friendly. Summary of the Invention [Problem to be solved by the invention]

[0007] The present invention provides an engineered aminotransferase polypeptide that is capable of asymmetric synthesis of chiral amine compounds, particularly the ubrogepant intermediate L1, and has high stereoselectivity, catalytic activity, and stability. The present invention also provides a gene encoding the engineered aminotransferase polypeptide, a recombinant expression vector containing the gene, an engineered strain, an efficient method for preparing the same, a process for asymmetric synthesis of L1 using the engineered aminotransferase polypeptide, and a process for purifying the product. [Means for solving the problem]

[0008] A first aspect of the present invention provides improved engineered aminotransferase polypeptides. Such engineered polypeptides have been engineered by an artificial directed evolution process to generate mutations, such as substitutions, insertions, or deletions of a specific number of amino acid residues. To obtain an aminotransferase active in the reaction shown in Figure 2, JPEG0007764620000004.jpg6170 We screened a library of aminotransferase enzymes and ultimately identified an aminotransferase having the sequence shown in SEQ ID NO:2, which is active in the reaction shown in Figure 2. SEQ ID NO:2 was developed from a wild-type aminotransferase derived from Aspergillus fumigatus. However, SEQ ID NO:2 has low activity and stereoselectivity for the substrate S1 and low solvent tolerance. Our findings showed that when the reaction shown in Figure 2 was performed using SEQ ID NO:2, the reaction yield was 35% when the substrate S1 loading amount was 5 g / L and the aminotransferase loading amount was 10 g / L, and the reaction time was 24 hours. Furthermore, high-concentration solvents such as methanol and DMSO have an inhibitory effect on SEQ ID NO:2. For example, if the activity of SEQ ID NO:2 in 20% methanol is defined as 100%, the relative activities of SEQ ID NO:2 in 35% and 50% methanol were 59% and 43%, respectively, and the relative activities of the aminotransferase in 20% DMSO, 35% DMSO, and 50% DMSO were 74%, 23%, and 8%, respectively. In the methanol-based reaction system, the dr value of the product catalyzed by SEQ ID NO:2 was 1.7, while in the DMSO system it was 0.3. For this aminotransferase to achieve industrial production of L1, it is necessary to engineer it to improve its activity and selectivity.

[0009] The present invention uses computational biology techniques to construct models and conduct virtual screening of mutants of aminotransferase SEQ ID NO:2. First, 112 stable mutants were obtained. Then, using activity virtual screening techniques, 40 mutants were selected from the 112 stable mutants that potentially contribute to improving the activity of catalyzing the reaction shown in Figure 2. Next, the inventors performed genetic construction and recombinant expression of these 40 mutants predicted by virtual screening in the laboratory and experimentally verified their performance in catalyzing the reaction shown in Figure 2 by setting appropriate reaction conditions. Finally, 15 mutants with improved catalytic activity and / or selectivity for the production of S1 to L1 were identified. Among them, SEQ ID NO:24 performed better. Compared to SEQ ID NO:2, SEQ ID NO:24 contains the mutation W183A. Based on these experimentally verified 15 mutants, the inventors conducted a new round of virtual screening of a combinatorial mutation library and identified seven beneficial mutants suitable for combination. Next, we constructed a combinatorial mutation library containing these seven beneficial mutations, screened this library using experimental methods, and finally obtained the optimal mutant SEQ ID NO: 130. Compared with SEQ ID NO: 2, the amino acid mutations contained in SEQ ID NO: 130 are T52Y, Q53T, W183A, and N190I.

[0010] The engineered aminotransferase polypeptides provided herein are active for the reactions shown in Figure 2 and comprise an amino acid sequence having one or more residue differences compared to the SEQ ID NO:2 sequence at amino acid residue positions corresponding to X52, X53, X115, X126, X146, X183, and X190.

[0011] Additionally, compared to the sequence of SEQ ID NO:2, the engineered aminotransferase polypeptides provided herein include amino acid sequences that include at least one of the following characteristics: T52Y, Q53TKFEH, N115GE, R126L, I146Q, W183AST, N190LI, and may also include insertions or deletions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 21, 22, 23, 24, 25 or more amino acid residues.

[0012] More specifically, in some embodiments, an improved engineered aminotransferase polypeptide based on SEQ ID NO:2 is an aminotransferase polypeptide having the corresponding SEQ ID NO:4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 200, 201 , 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, and 158.

[0013] In some embodiments, the improved engineered aminotransferase polypeptide is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158. These include amino acid sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a reference sequence of any of the following:

[0014] The identity between two amino acid sequences or two nucleotide sequences can be calculated using algorithms commonly used in the field, such as NCBI Blastp and Blastn software, according to default parameters, or the Clustal W algorithm (Nucleic Acid Research, 22 (22): 4673-4680, 1994). For example, using the Clustal W algorithm, the amino acid sequence identity between SEQ ID NO: 2 and SEQ ID NO: 130 is 98.7%.

[0015] In another aspect, the invention provides polynucleotide sequences encoding engineered aminotransferase polypeptides. In some embodiments, the polynucleotide may be part of an expression vector having one or more regulatory sequences for expressing the engineered aminotransferase polypeptide. In some embodiments, the polynucleotide is selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 9, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157.

[0016] As known to those skilled in the art, due to the degeneracy of nucleotide codons, the sequences of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, Polynucleotide sequences encoding the amino acid sequences of 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, and 158 are set forth in SEQ ID NOs. NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47 , 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 , 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157. Nucleic acid sequences encoding engineered aminotransferases of the present invention are set forth in the sequence listing under SEQ ID NOs. NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104 , 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158.

[0017] In another aspect, the disclosure provides polynucleotides encoding engineered aminotransferases or expression vectors capable of expressing the engineered aminotransferases, and host cells. In some embodiments, the host cells may be bacterial host cells, such as E. coli. The host cells can be used to express and isolate the engineered aminotransferases described herein, or can be used directly in reactions to convert substrates to products.

[0018] In some embodiments, engineered aminotransferases in the form of whole cells, crude extracts, isolated polypeptides, or purified polypeptides can be used alone or in immobilized form (e.g., immobilized on a resin).

[0019] The engineered aminotransferase polypeptides disclosed in the present invention can catalyze the conversion of a ketone substrate represented by structural formula XI to an amine product represented by structural formula I.

[0020] JPEG0007764620000005.jpg73170 (where R 1 , R 2 , R 3 , R 4 , and R 5 may be optionally substituted -H, C1-C6 hydrocarbyl, halogen (e.g., -F, -Cl, -Br, -I), -NO:2, -NO, -S02R' or -SOR', -SR', -NR'R', -OR', -C02R' or -COR', -C(O)NR', ​​-SON2NH2 or -SONH2, -CN, CF3, and R 6 may be a C1-C6 hydrocarbyl, a C1-C6 halogenated hydrocarbon, or a C1-C6 hydroxy-substituted hydrocarbon; R 7 may be a C1-C6 hydrocarbyl, a C1-C6 halogenated hydrocarbon, or a C1-C6 hydroxy-substituted hydrocarbon; R 8may be a CBZ protecting group, a BOC protecting group, a Fomc protecting group, a Bn protecting group, or a methoxy(ethoxy)carbonyl protecting group. Each R' is independently selected from H or a C1-C4 hydrocarbyl.

[0021] The amine product of formula I is a mixture of one or more of the chiral amine products of formulas II-V.

[0022] JPEG0007764620000006.jpg60170

[0023] Due to the activity of the ester group in the compound I structure, under appropriate reaction conditions, the enzyme-catalyzed amine product of formula I can spontaneously undergo ring formation to form the lactam of formula VI.

[0024] JPEG0007764620000007.jpg61153

[0025] The chiral amine product of formula VI is a mixture of one or more compounds of the chiral amine products of formulas VII-X below.

[0026] JPEG0007764620000008.jpg57153

[0027] The substrate, structural formula XI, corresponding to the chiral amine product, structural formula IX, which can be produced upon catalysis by the engineered aminotransferase polypeptides disclosed herein is shown below:

[0028] JPEG0007764620000009.jpg61153

[0029] Preferably, the engineered aminotransferase polypeptides disclosed in the present invention have significant catalytic activity towards substrate S1, the structural formula of which is shown below:

[0030] JPEG0007764620000010.jpg64170

[0031] S1 may include the following four different isomers: ST1, ST2, SD1 or SD2.

[0032] JPEG0007764620000011.jpg40170

[0033] The engineered aminotransferase polypeptides disclosed in the present invention may convert S1 to I1.

[0034] JPEG0007764620000012.jpg67170

[0035] I1 may include the following four different isomers IT1, IT2, ID1 or ID2.

[0036] JPEG0007764620000013.jpg30131

[0037] A compound represented by structural formula IT represents IT1 and / or IT2.

[0038] JPEG0007764620000014.jpg53131

[0039] The ester bond on the I1 structure may spontaneously break to form a ring, forming the corresponding compounds designated T1, T2, D1, and D2.

[0040] JPEG0007764620000015.jpg41131

[0041] In the products produced by the engineered aminotransferase polypeptides disclosed herein catalyzing substrate S1, IT1 and IT2, and T1 and T2, are excess products. T1 and T2 are represented by the structural formula L1.

[0042] JPEG0007764620000016.jpg47131

[0043] In the present invention, the "diastereomeric ratio" (i.e., diastereomeric ratio, abbreviated as dr) is the ratio of the sum of the concentrations of diastereomeric compounds T1 and T2 in the product to the sum of the concentrations of diastereomeric compounds D1 and D2, and is calculated by dr = [T1 + T2] / [D1 + D2].

[0044] In some embodiments, the engineered aminotransferase polypeptide has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity compared to SEQ ID NO:2 and is capable of converting compound S1 to one or more of the amine products compounds T1, T2, D1, and D2.

[0045] In some embodiments, the dr value of the product (i.e., [T1+T2] / [D1+D2]) is at least 1, 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more.

[0046] Specific embodiments of engineered aminotransferase polypeptides for use in the methods are further described in the Detailed Description of the Invention. Improved engineered aminotransferase polypeptides that can be used in the above methods include those set forth in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 149, 150, 151, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 163, 164, 165, 166, 168, 170, 172, 174, 176, 178, 179, 180, 182, 184, 186, 188, 189, 200, 201, 202, 203, 204, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158. Any of the methods for preparing a compound of Formula I, Formula VI, Formula II or Formula L1 using the engineered polypeptides disclosed herein can be carried out under a range of suitable reaction conditions, including, but not limited to, ranges of amino donor, pH, temperature, buffer, solvent system, substrate loading, polypeptide loading, cofactor loading, pressure, and reaction time. For example, in some embodiments, compounds of formula T1 and T2 may be prepared using suitable reaction conditions including (a) a substrate S1 loading of about 10 g / L to 100 g / L, (b) an engineering polypeptide loading of about 1 g / L to 50 g / L, (c) an isopropylamine loading of about 0.1 M to 4.0 M, (d) a pH of about 7.0 to 11.5, (e) a temperature of about 10° C. to 65° C., and (f) 0% to 70% solvent. Organic solvents described herein include, but are not limited to, methanol, dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylformamide (DMF), methyl tert-butyl ether (MTBE), isopropyl acetate, ethanol, propanol, isopropanol (IPA), or a mixture of two or more thereof.

[0047] detail definition With respect to the present disclosure, unless expressly defined otherwise, technical and scientific terms used herein have the meanings that are commonly understood by those of ordinary skill in the art.

[0048] "Protein," "polypeptide," and "peptide" are used interchangeably herein and refer to polymers of at least two amino acids covalently joined by amide bonds, regardless of length or post-translational modification (e.g., glycosylation, phosphorylation, lipidation, myristoylation, ubiquitination, etc.). This definition includes D- and L-amino acids and mixtures of D- and L-amino acids.

[0049] The terms "engineered aminotransferase," "engineered aminotransferase polypeptide," "improved aminotransferase polypeptide," and "engineered polypeptide" are used interchangeably herein.

[0050] "Bacteria" or "wet bacteria" refers to host cells expressing a polypeptide or engineered polypeptide, including wet bacteria obtained by the preparation process shown in Example 2.

[0051] "Polynucleotide" and "nucleic acid" are used interchangeably herein.

[0052] As used herein, "cofactor" refers to a non-protein compound that acts in conjunction with an enzyme in a catalytic reaction. As used herein, "cofactor" is intended to include compounds of the vitamin B6 family, such as pyridoxal-5'-phosphate (PLP), pyridoxine (pyridoxol, PN), pyridoxal (PL), pyridoxamine (PM), pyridoxinephosphate (PNP), and pyridoxaminephosphate (PMP), which are sometimes referred to as coenzymes. "PLP," "pyridoxal-5'-phosphate," "pyridoxal-5'-phosphate," "PYP," and "P5P" are used interchangeably herein to refer to compounds that function as cofactors in enzyme-catalyzed reactions.

[0053] "Coding sequence" refers to a nucleic acid segment (eg, a gene) that codes for the amino acid sequence of a protein.

[0054] "Naturally-occurring" or "wild-type" refers to a form found in nature. For example, a naturally-occurring or wild-type polypeptide or polynucleotide sequence is one that exists in an organism, isolatable from a source in nature, and has not been intentionally modified by human manipulation.

[0055] "Recombinant" or "engineered" or "non-naturally occurring," when used to refer to, for example, a cell, nucleic acid, or polypeptide, refers to material that is altered in a way that does not occur in nature, or that is the same but produced or obtained from synthetic materials and / or by manipulation using recombinant techniques, or material that corresponds to the native or inherent form of such material.

[0056] "Sequence identity" and "homology" are used interchangeably herein to refer to a comparison between polynucleotides or polypeptides ("sequence identity" and "homology" are typically expressed as a percentage) and are determined by comparing two best-aligned sequences within a comparison window, where a portion of the polynucleotide or polypeptide sequence within the comparison window may contain additions or deletions (i.e., gaps) relative to the reference sequence to best align the two sequences. The percentage is obtained by determining the number of positions in the two sequences where the same nucleic acid base or amino acid residue occurs to obtain the number of matching positions, dividing this number of matching positions by the total number of positions within the comparison window, and multiplying by 100 to obtain the percentage of sequence identity. Alternatively, the percentage may be obtained by determining the number of positions where the same nucleic acid base or amino acid residue occurs in both sequences, or the number of positions where the nucleic acid base or amino acid residue aligns with a gap, to obtain the number of matching positions, dividing this number of matching positions by the total number of positions within the comparison window, and multiplying by 100 to obtain the percentage of sequence identity. Those skilled in the art will appreciate that there are many established algorithms available to align two sequences. Sequences for comparison can be best aligned using, for example, the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the similarity search method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, computer implementations of these algorithms (GAP, BESTFIT, FASTA, or TFASTA in the GCCG Wisconsin package), or by visual inspection (see generally, Current Protocols in Molecular Biology, edited by F.M. Ausubel et al., Current Protocols, a joint venture of Greene Publishing Associates Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).Examples of suitable algorithms for determining percentage sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms described in Altschul et al., 1990, J. Mol. Biol. 215:403-410, and Altschul et al., 1977, Nucleic Acids Res. 3389-3402, respectively. Software used to perform BLAST analysis is publicly available from the website of the National Center for Biotechnology Information. This algorithm involves identifying high-scoring sequence pairs (HSPs) by first identifying short words of length W in the query sequence that match or meet some positive threshold score T when compared with words of the same length in database sequences. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits serve as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence to the point where the cumulative alignment score cannot be increased. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for matching residue pairs, always >0) and N (penalty score for mismatching residues, always <0). For amino acid sequences, a score matrix is ​​used to calculate the cumulative score. Extension of the word hit string in each direction terminates when the accumulation of one or more negative-scoring residue alignments, which would reduce the cumulative alignment score by an amount X from the maximum achieved, causes the cumulative score to fall below 0, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses default values ​​of word length (W) 11, expectation (E) 10, M = 5, N = -4, and comparison of both strands.For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, 1989, Proc Natl Acad Sci USA 89:10915) as defaults. Exemplary sequence alignments and determinations of percent sequence identity can be performed using the BESTFIT or GAP programs in the GCG Wisconsin software package (Accelrys, Madison, WI) with the default parameters provided. A "reference sequence" refers to a limiting sequence used as a basis for sequence comparison. A reference sequence may be a subset of a larger sequence, such as a fragment of a full-length gene or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotides or amino acid residues in length, at least 25 residues in length, at least 50 residues in length, or the full length of the nucleic acid or polypeptide. Because two polynucleotides or polypeptides may each contain (1) similar sequences (i.e., portions of the complete sequence) between the two sequences and (2) additional sequences that differ between the two sequences, comparison of sequences between two (or more) polynucleotides or polypeptides is typically performed by comparing the sequences of the two polynucleotides or polypeptides within a "comparison window" to identify and compare local regions of sequence similarity. In some embodiments, the term "reference sequence" is not intended to be limited to wild-type sequences and may include engineered or modified sequences. A "comparison window" refers to a conceptual fragment of at least about 20 contiguous nucleotide positions or amino acid residues within which a sequence can be compared to a reference sequence of at least 20 contiguous nucleotides or amino acid residues, where the portion of the sequence within the comparison window may contain no more than 20% additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions) for optimal alignment of the two sequences. The comparison window can be longer than 20 contiguous residues and optionally includes a window of 30, 40, 50, 100, or more.When used with numbers for a specified amino acid sequence or polynucleotide sequence, "corresponding to," "referring to," or "relative to" refers to the residue number of the specified reference sequence when the specified amino acid sequence or polynucleotide sequence is compared to the reference sequence. In other words, residue numbers or residue positions in a given sequence are assigned based on the reference sequence, not the actual numerical positions of the residues in the given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as the amino acid sequence of an engineered polypeptide, may be aligned with a reference sequence by introducing gaps to optimize residue matches between the two sequences. In these cases, even though gaps exist, residue numbers in a given amino acid or polynucleotide sequence are formulated relative to the reference sequence to which it is aligned. An "amino acid difference" or "residue difference" refers to the difference in the amino acid residue at a position in a polypeptide sequence relative to the amino acid residue at the corresponding position in the reference sequence. The position of the amino acid difference is generally referred to herein as "Xn," where n refers to the corresponding position in the reference sequence underlying the residue difference. For example, "residue difference at position X183 relative to SEQ ID NO:2" refers to an amino acid residue difference at the polypeptide position corresponding to position 183 of SEQ ID NO:2. Thus, if a reference polypeptide of SEQ ID NO:2 has tryptophan at position 183, then "residue difference at position X183 relative to SEQ ID NO:2" refers to an amino acid substitution of any residue other than tryptophan at the polypeptide position corresponding to position 183 of SEQ ID NO:2. In most examples herein, specific amino acid residue differences at a position are designated "XnY," where "Xn" refers to the corresponding position above and "Y" is the one-letter code for the amino acid that appears in the engineered polypeptide (i.e., the residue that differs from that in the reference polypeptide). In some examples (e.g., Table 2), the disclosure also provides specific amino acid differences represented by the conventional code "AnB," where A is the one-letter code for the residue in the reference sequence, "n" is the number of the residue position in the reference sequence, and B is the one-letter code for the residue substitution in the sequence of the engineered polypeptide.In some examples, a polypeptide of the present disclosure may contain one or more amino acid residue differences relative to a reference sequence, represented by a list of specific positions where residue differences exist compared to the reference sequence. "Deletion" refers to modification of a polypeptide by removing one or more amino acids from a reference polypeptide. Deletions may include removal of one or more amino acids, two or more amino acids, five or more amino acids, ten or more amino acids, fifteen or more amino acids, or twenty or more amino acids, up to 10% of the total number of amino acids comprising the reference enzyme, or up to 20% of the total number of amino acids comprising the reference enzyme, while retaining the activity of the engineered aminotransferase for the reaction shown in FIG. 1. Deletions may include internal and / or terminal portions of the polypeptide. In various embodiments, deletions may comprise contiguous segments or may be discontinuous. "Insertion" refers to modification of a polypeptide by adding one or more amino acids from a reference polypeptide. In some embodiments, engineered polypeptides of the present disclosure include one or more amino acid insertions into naturally occurring aminotransferase polypeptides and one or more amino acid insertions into other engineered polypeptides. Insertions may be made internally in the polypeptide, or at the carboxy or amino terminus. As used herein, an insertion includes fusion proteins, as known in the art. An insertion may be a contiguous segment of amino acids or may be separated by one or more amino acids in a naturally occurring polypeptide. As used herein, a "fragment" refers to a polypeptide having an amino- and / or carboxy-terminal deletion, but in which the retained amino acid sequence is the same as the corresponding positions in the sequence. Fragments may be at least 10 amino acids long, at least 20 amino acids long, at least 50 amino acids long, or longer, and may be up to 70%, 80%, 90%, 95%, 98%, and 99% of the full-length engineered polypeptide.

[0057] An "isolated polypeptide" or "purified polypeptide" refers to a polypeptide that has been substantially isolated from other materials that are naturally associated with it, such as proteins, lipids, and polynucleotides. The term includes polypeptides that have been removed or purified from their naturally occurring environment or expression system (e.g., a host cell or in vitro synthesis). An engineered polypeptide may be present intracellularly, in cell culture medium, or prepared in various forms, such as a lysate or isolated preparation. Thus, in some embodiments, an engineered polypeptide may be an isolated polypeptide.

[0058] A "chiral center" refers to a carbon atom connecting four different groups.

[0059] "Stereoselectivity" refers to the preferential formation of one stereoisomer over another or multiple isomers in a chemical or enzymatic reaction. Stereoselectivity can be partial, with one stereoisomer being formed in preference to others, or complete, with only one stereoisomer being formed. Stereoselectivity is also referred to as diastereoisomer selectivity when the stereoisomers are diastereoisomers, and the ratio of one diastereomer to the other is usually reported as the "diastereomeric ratio" (dr for short). This ratio is usually reported alternatively in the art as the "diastereomeric ratio" (dr for short), calculated from the formula {concentration of major diastereomer} / {concentration of minor diastereomer}.

[0060] "Stereoisomer," "stereoisomeric form," and similar expressions are used interchangeably herein and refer to all isomers whose molecules differ only in the orientation of their atoms in space. This includes enantiomers and isomers of compounds with multiple chiral centers that are not mirror images of one another (i.e., "diastereomers").

[0061] "Improved enzyme properties" refers to any improved enzyme properties that an engineered polypeptide exhibits compared to a reference sequence, the evolution of which begins with aminotransferase SEQ ID NO: 22. Desirable enzyme properties for improvement include, but are not limited to, enzyme activity (which can be expressed as a percentage of substrate conversion), thermostability, solution stability (e.g., stability to alcoholic compounds), pH activity profile, cofactor requirements, tolerance to inhibitors (e.g., sediment or product inhibition), stereospecificity, and stereoselectivity.

[0062] "Reaction yield" refers to the molar percentage of the product produced in a reaction system relative to the initial input substrate under specified reaction conditions and within a specified reaction time. Therefore, the "enzyme activity" or "activity" of an aminotransferase or engineered polypeptide can be expressed as a "reaction yield." The reaction is generally calculated by taking a sample and measuring the molar concentrations of the product and starting substrate in the reaction system, as {molar concentration of product} / {molar concentration of starting substrate}.

[0063] "Thermostable" refers to an engineered polypeptide that retains activity similar to the starting template after exposure to elevated temperatures (eg, 65°C or higher) for a period of time (eg, 0.5 hours or more).

[0064] "Solvent stability" or "solvent resistance" refers to the ability of an engineered polypeptide to maintain activity similar to that of the starting template after exposure to various concentrations (e.g., 5-99%) of solvents (e.g., methanol, ethanol, isopropanol, dimethyl sulfoxide (DMSO), tetrahydrofuran, 2-methyltetrahydrofuran, acetone, toluene, butyl acetate, methyl tert-butyl ether, etc.) for a period of time (e.g., 0.5-24 hours).

[0065] "Suitable reaction conditions" refer to conditions in a biocatalytic reaction solution (e.g., ranges of enzyme loading, substrate loading, amino donor loading, cofactor loading, temperature, pH, buffer, cosolvent, etc.) that allow an engineered polypeptide according to the present disclosure to convert a substrate into a desired product compound. Exemplary "suitable reaction conditions" are provided in the present disclosure and validated by the Examples. A compound may be referred to by its chemical structure and / or chemical name. If the chemical structure conflicts with the chemical name, the chemical structure is determinative of the compound.

[0066] Directed evolution process and developed engineering aminotransferases The engineered aminotransferase polypeptides disclosed in the present invention have been modified through an innovative directed evolution process, resulting in mutations such as substitution, insertion, or deletion of a specific number of amino acid residues. The inventors have found that the aminotransferase corresponding to SEQ ID NO:2 is active against S1, but with low activity, low chiral selectivity, and poor solvent tolerance. To develop an engineered aminotransferase with superior performance suitable for the reaction shown in Figure 2, the present invention designed and implemented three research and development stages, as shown in Table 1. Each stage has a different research and development focus, and different screening reaction conditions are employed to achieve a targeted result. The optimal engineered aminotransferase polypeptides obtained in each stage are listed in Table 2.

[0067] JPEG0007764620000017.jpg73137

[0068] The main objective of Phase I is to screen the developed engineering aminotransferase enzyme library to find an aminotransferase catalyst that is catalytically active in producing product L1 from substrate S1 and can be used directly for industrial application or as a starting enzyme for directed evolution. Our screening results indicate that SEQ ID NO:2 is the most suitable evolutionary starting enzyme developed from the wild-type aminotransferase from Aspergillus fumigatus (NCBI: XP_748821.1). Table 2 shows the residue differences of SEQ ID NO:2 compared to the wild-type enzyme and the sequence identity of SEQ ID NO:2 compared to the wild-type enzyme. The amino acid sequence identity was calculated using the Clustal W algorithm (Nucleic Acid Research, 22(22):4673-4680, 1994). SEQ ID NO:2 needs to be modified through directed evolution techniques to further improve its activity, stability, selectivity, and other properties to be suitable for industrial application.

[0069] JPEG0007764620000018.jpg94137

[0070] The main objective of Phase II is to discover amino acid mutations that have significant effects on enzyme activity, stability, and selectivity, and provide data support for subsequent directed evolution library design. The present invention uses bioinformatics and computational biology techniques to perform virtual screening of mutants of aminotransferase SEQ ID NO:2, and the general process of this virtual screening method is as follows:

[0071] The virtual screening process is as follows:

[0072] Step 1: Homology modeling: For SEQ ID NO:2, homology modeling was performed through Yasara software using PDBID 4UUG as template, and the modeling parameters are shown in Table 3.

[0073] JPEG0007764620000019.jpg81137

[0074] Step 2: Autodock docking: Four chiral substrates, ST1, ST2, SD1, and SD2, were docked with the target enzyme using the Autodock method in Yasara software, resulting in the enzyme-substrate complex shown in Figure 3. Then, amino acids within 5 Å of the substrate were selected as candidate mutation sites (T52, Q53, T60, L113, N115, R126, L141, L143, I146, L148, W183, N190, G215, S273, T274, and A275).

[0075] Step 3: Rosetta stability virtual screening: Using the Cartesian_ddg algorithm in Rosetta software, single-point saturation mutation stability virtual screening was performed on the candidate sites obtained in the previous step. The number of virtual screenings was 16 * 19 = 304 single-site mutations. As a result of the screening, 112 single-site mutations beneficial to stability were found. The results are shown in Table 4.

[0076] JPEG0007764620000020.jpg94170

[0077] The evaluation criteria for the calculation results of the stability of mutants are as follows: if ΔΔG≦-1 kcal / mol, it is a stable mutant; if ΔΔG≧1 kcal / mol, it is an unstable mutant; and if -1 kcal / mol<ΔΔG<1 kcal / mol, it is an invalid mutant. This criterion also applies to the evaluation of stability results obtained by other calculation methods.

[0078] Step 4: Activity Virtual Screening: The reaction energy barrier is the minimum energy required for a reactant molecule to become an activated molecule. The magnitude of the energy barrier reflects the difficulty of the reaction. Therefore, the present invention employs a process based on empirical valence bond theory to realize batch calculation of the reaction energy barrier, and mutants with improved activity were obtained by comparing the difference in the calculated reaction energy barrier between SEQ ID NO:2 and the mutants. This screening step yielded a total of 40 mutations that improved the activity of the target substrate T1 or T2. The results are shown in Table 5.

[0079] JPEG0007764620000021.jpg68170

[0080] The final experimental screening results showed that 15 of the 40 virtual screening mutations showed similar or significantly improved activity in improving the dr value of T1 or T2 production. Among them, the better mutant enzyme was SEQ ID NO:24, with the mutation W183A. For a specific screening example, see Example 5. The 15 advantageous mutations and their corresponding activities and selectivities are listed in Table 6.

[0081] JPEG0007764620000022.jpg108170

[0082] The mutation library can be constructed by site-specific mutagenesis PCR or multi-site mutagenesis PCR, which are well known in the art (see "Mutagenesis and Synthesis of Novel Recombinant Genes Using PCR", Chapter 32, in PCR Primer, 2nd edition (eds. Dieffenbach and Dveksler), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2003).

[0083] The main goal of Phase III is to obtain an enzyme with significantly improved activity, selectivity, and solvent tolerance (stability). In the previous two phases, we discovered that when methanol or DMSO alone is used as a cosolvent for substrate S1, each has its own advantages and disadvantages. Using methanol as a cosolvent increases the solubility of the substrate in the cosolvent, but the substrate is prone to hydrolysis. Using DMSO as a cosolvent reduces the solubility of substrate S1 in the system, affecting the in situ racemization of the substrate (i.e., the conversion of ST1 and ST2 to SD1 and SD2). To address the drawbacks of using a single solvent for the reaction, we inventively used a DMSO / ACN mixed solvent as the reaction solvent instead of a single solvent. The solubility of substrate S1 in ACN is much higher than that in DMSO, and the substrate is not easily hydrolyzed in either DMSO or ACN. Therefore, using a mixed solvent improves the solubility of substrate S1 in the reaction system, promotes in situ racemization of the substrate, significantly reduces substrate hydrolysis due to the use of alcoholic solvents, and partially avoids the inhibition of enzyme activity caused by high concentrations of single acetonitrile. To obtain improved enzyme performance, we designed a combinatorial mutation library by combining the 15 favorable mutations screened in Phase II to obtain a combinatorial mutation library containing 1,728 protein sequences. We then performed Rosetta stability and activity virtual screening of the combinatorial mutations. Using the first 20% of the mutation combinations with improved activity, we determined the probability of occurrence of dominant amino acids. Finally, we obtained the optimal amino acid combinations for each site. The results are shown in Table 7.

[0084] JPEG0007764620000023.jpg42170

[0085] Finally, based on SEQ ID NO:24, the optimal mutations obtained at each site were combined into an experimental screening library, which was then screened using the Phase III screening reaction conditions in Table 1. For a specific screening example, see Example 7. Finally, an aminotransferase mutant, SEQ ID NO:130, was obtained, which exhibits significantly improved chiral selectivity and activity. Compared with SEQ ID NO:2, it contains four amino acid mutations: SEQ ID NOs:T52Y, Q53T, W183A, and N190I. Table 8 shows the engineered aminotransferase polypeptides corresponding to each mutation combination, the improved activity compared to SEQ ID NO:2, and the resulting dr values ​​of the catalytically generated products.

[0086] JPEG0007764620000024.jpg184170JPEG0007764620000025.jpg243170JPEG0007764620000026.jpg239170

[0087] JPEG0007764620000027.jpg48170

[0088] The paper "Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant" discloses that the product of aminotransferases ATA-412 and ATA-426 has a dr value of 61 at a substrate concentration of 50 g / L. The engineered aminotransferase polypeptides developed in the present invention have superior activity, selectivity, stability (including thermal stability), solvent tolerance, and substrate tolerance. Furthermore, the present invention optimizes the solvent used in the reaction, achieving a much higher solubility of substrate S1 in aqueous ACN than in aqueous DMSO. To avoid damage to enzyme activity caused by a single high-concentration ACN solvent and improve the solubility of substrate S1 in aqueous systems, the present invention innovatively uses a mixed solvent of ACN and DMSO as the reaction solvent. Furthermore, it has been demonstrated that ester hydrolysis of substrate S1 in a mixed solvent system is very effectively controlled. Therefore, the engineered aminotransferase polypeptides disclosed in the present invention are more suitable for industrial production scenarios.

[0089] Polynucleotides, control sequences, expression vectors and host cells useful for preparing engineered aminotransferase polypeptides In another aspect, the present disclosure provides polynucleotides encoding engineered polypeptides having aminotransferase activity as described herein. The polynucleotides can be operably linked to one or more heterologous regulatory sequences that control gene expression to generate recombinant polynucleotides capable of expressing the polypeptides. Expression constructs containing heterologous polynucleotides encoding engineered aminotransferases can be introduced into suitable host cells to express the corresponding engineered aminotransferase polypeptides. As will be apparent to those skilled in the art, the availability of protein sequences and knowledge of the codons corresponding to various amino acids provides a description of all polynucleotides capable of encoding a target protein sequence. The degeneracy of the genetic code, in which the same amino acids are coded for by alternative or synonymous codons, allows for the generation of a vast number of nucleic acids, all of which encode the improved aminotransferase polypeptides disclosed herein. Thus, after determining a particular amino acid sequence, one skilled in the art can generate any number of different nucleic acids by modifying only the sequence of one or more codons without altering the amino acid sequence of the protein.In this regard, the present disclosure specifically contemplates all possible modifications of polynucleotides that can be prepared by selecting combinations based on possible codon choices, and for any polypeptide herein, the amino acid sequences of exemplary engineered polypeptides provided in Tables 6 and 8, and SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104, 106, 108, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 15 150, 152, 154, 156, 158, all of which modifications are considered to be specifically disclosed.

[0090] In various embodiments, codons are preferably selected to be compatible with the host cell in which the protein will be produced, for example, bacterially preferred codons are used to express a gene in bacteria, yeast preferred codons are used to express a gene in yeast, and mammalian preferred codons are used to express a gene in mammalian cells.

[0091] In some embodiments, the polynucleotide is selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 220, 221, 222, 223, 224 and encoding an aminotransferase polypeptide comprising an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a reference sequence selected from the group consisting of: 42, 144, 146, 148, 150, 152, 154, 156, and 158, wherein the polypeptide has one or more of the improved properties described herein, such as aminotransferase activity, increased activity compared to the polypeptide of SEQ ID NO:2, or the ability to convert compound S1 to product T2 or T2.

[0092] In some embodiments, the polynucleotide encodes an engineered aminotransferase polypeptide comprising an amino acid sequence having one or more amino acid residue differences compared to SEQ ID NO:2 and having the above percentage identity. In some embodiments, the disclosure provides engineered polypeptides with aminotransferase activity that comprise at least 80% sequence identity to the reference sequence of SEQ ID NO:2 and have a combination of residue differences at positions selected from X52, X53, X115, X126, X146, X183, and X190.

[0093] In some embodiments, the polynucleotide encoding the engineered aminotransferase polypeptide is selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157.

[0094] In some embodiments, the polynucleotide encodes a polypeptide described herein but has about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity at the nucleotide level to a reference polynucleotide encoding an engineered aminotransferase.

[0095] In some embodiments, the reference polynucleotide sequence is selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93 , 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157.

[0096] An isolated polynucleotide encoding an engineered aminotransferase polypeptide can be manipulated in a variety of ways to provide for expression of the polypeptide, including further sequence modification by codon optimization to improve expression, insertion into an appropriate expression element, with or without additional regulatory sequences, and transformation into a host cell suitable for expression and production of the polypeptide. Depending on the expression vector, manipulation of the isolated polynucleotide may be desirable or necessary before inserting it into the vector. Techniques for modifying polynucleotides and nucleic acid sequences using recombinant DNA methods are well known in the art. Guidance is provided in Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, and Current Protocols in Molecular Biology, Ausubel, F. (ed.), Greene Pub. Associates, 1998, updated 2010.

[0097] In another aspect, the present disclosure also relates to a recombinant expression vector comprising a polynucleotide encoding an engineered aminotransferase polypeptide or variant thereof and one or more expression control regions, such as a promoter-terminator and an origin of replication, depending on the type of host into which it will be introduced. Alternatively, the nucleic acid sequences of the present disclosure can be expressed by inserting the nucleic acid sequence or a nucleic acid construct containing the sequence into an appropriate expression vector. When producing an expression vector, the coding sequence is placed within the vector so that it is operably linked to appropriate control sequences for expression. The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently used in recombinant DNA processes and can result in the expression of a polynucleotide sequence. The choice of vector usually depends on the compatibility of the vector with the host cell into which it will be introduced. The vector may be a linear plasmid or a closed circular plasmid. The expression vector may also be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity whose replication is independent of chromosomal replication, such as a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may include any means for ensuring self-replication. Alternatively, the vector may be one that, when introduced into a host cell, is integrated into the genome and replicates along with the chromosome into which it has been integrated. Furthermore, a single vector or plasmid, or two or more vectors or plasmids that together comprise the total DNA to be introduced into the host cell genome, can be used. Many expression vectors useful for embodiments of the present disclosure are commercially available. An exemplary expression vector can be prepared by operably linking a polynucleotide encoding an improved aminotransferase polypeptide to the plasmid pACYC-Duet-1 (Novagen).

[0098] In another aspect, the present disclosure provides a host cell comprising a polynucleotide encoding an improved aminotransferase polypeptide of the present disclosure, the polynucleotide being operably linked to one or more regulatory sequences for expression of the aminotransferase in the host cell. Host cells for expressing polypeptides encoded by expression vectors of the present disclosure are well known in the art and include, but are not limited to, bacterial cells such as Escherichia coli, Arthrobacter sp. KNK168, Streptomyces sp., and Salmonella typhimurium cells; fungal cells such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris); insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, BHK, 293, and Bowes melanoma cells; and plant cells. An exemplary host cell is E. coli BL21(DE3). The host cells may be wild-type or engineered cells that have undergone genome editing, such as knocking out the wild-type aminotransferase gene contained in the genome of the host cell. Suitable culture media and growth conditions for the host cells are well known in the art.

[0099] Polynucleotides for expressing aminotransferases can be introduced into cells by a variety of methods known in the art, including electroporation, bioparticle bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion. Various methods for introducing polynucleotides into cells will be apparent to those skilled in the art.

[0100] Methods for producing engineered aminotransferase polypeptides If the sequence of an engineered polypeptide is known, a polynucleotide encoding that polypeptide can be prepared by standard solid-phase synthesis methods according to known synthesis methods. In some embodiments, fragments of up to about 100 bases can be synthesized separately and then ligated (e.g., by enzymatic or chemical ligation or polymerase-mediated methods) to form any desired contiguous sequence. For example, polynucleotides and oligonucleotides of the present disclosure can be synthesized, for example, by the classical phosphoramidite method described in Beaucage et al., 1981, TetLett 22:1859-69, or by methods described in Matthes et al., 1984, EMBOJ. 3:801-05, e.g., as typically implemented in automated synthesis. According to the phosphoramidite method, oligonucleotides are synthesized, for example, in an automated DNA synthesizer, purified, annealed, ligated, and cloned into an appropriate vector. Essentially any nucleic acid can also be obtained from any of a variety of commercial sources.

[0101] In some embodiments, the disclosure also provides a method for preparing or making an engineered aminotransferase polypeptide, the method comprising culturing a host cell capable of expressing a polynucleotide encoding the engineered polypeptide under culture conditions suitable for expression of the polypeptide.

[0102] In some embodiments, the method for preparing a polypeptide further comprises isolating the polypeptide. The engineered polypeptide can be expressed in a suitable cell and isolated (or recovered) from the host cell and / or culture medium using any one or more of the well-known techniques for protein purification. Such techniques for protein purification include, among others, lysozyme treatment, sonication, filtration, salting out, heat treatment, ultracentrifugation, and chromatography.

[0103] Methods for using engineered aminotransferases and preparation of compounds using the same In another aspect, the improved engineered aminotransferase polypeptides described herein can convert a prochiral acceptor ketone compound to a chiral amine compound in the presence of an amino donor. The present disclosure also provides methods for preparing a wide range of Compound I or structural analogs thereof using the engineered aminotransferase polypeptides disclosed herein. In some embodiments, the engineered aminotransferase polypeptides can be used in methods for preparing compounds of structural formula I.

[0104] JPEG0007764620000028.jpg59170 (where R 1 , R 2 , R 3 , R 4 , and R 5 may be optionally substituted -H, C1-C6 hydrocarbyl, halogen (e.g., -F, -Cl, -Br, -I), -NO:2, -NO, -S02R' or -SOR', -SR', -NR'R', -OR', -C02R' or -COR', -C(O)NR', ​​-SON2NH2 or -SONH2, -CN, CF3, and R 6 may be a C1-C6 hydrocarbyl, a C1-C6 halogenated hydrocarbon, or a C1-C6 hydroxy-substituted hydrocarbon; R 7 may be a C1-C6 hydrocarbyl, a C1-C6 halogenated hydrocarbon, or a C1-C6 hydroxy-substituted hydrocarbon; R 8 may be a CBZ protecting group, a BOC protecting group, a Fomc protecting group, a Bn protecting group, or a methoxy(ethoxy)carbonyl protecting group. Each R' is independently selected from H or a C1-C4 hydrocarbyl. The amine product of formula I is a mixture of one or more of the chiral amine isomers of formulas II-VI.

[0105] JPEG0007764620000029.jpg59170

[0106] Due to the activity of the ester group in the compound I structure, under appropriate reaction conditions, such as appropriate temperature, pH, and solvent conditions, some of the amine products of formula I may spontaneously undergo cyclization to form lactams of formula VI.

[0107] JPEG0007764620000030.jpg63170

[0108] The amine product of formula VI is a mixture of one or more chiral amine isomers of formulas VII-X below.

[0109] JPEG0007764620000031.jpg67170

[0110] Substrates that can be catalyzed by aminotransferases to produce chiral amine products of formula IX are shown below as structure XI.

[0111] JPEG0007764620000032.jpg63170

[0112] Preferably, the engineered aminotransferase polypeptides disclosed in the present invention have significant catalytic activity towards substrate S1, the structural formula of which is shown below:

[0113] JPEG0007764620000033.jpg60170

[0114] S1 may include four different isomers: ST1, ST2, SD1 or SD2.

[0115] JPEG0007764620000034.jpg40170

[0116] The engineered aminotransferase polypeptides disclosed in the present invention are capable of converting S1 to I1.

[0117] JPEG0007764620000035.jpg65170

[0118] I1 may include four different isomers: IT1, IT2, ID1 or ID2.

[0119] JPEG0007764620000036.jpg38170

[0120] A compound represented by structural formula IT represents IT1 and / or IT2.

[0121] JPEG0007764620000037.jpg67170

[0122] The ester bond in the structure of I1 may spontaneously break to form a ring, forming the corresponding compounds denoted T1, T2, D1, and D2.

[0123] JPEG0007764620000038.jpg55170

[0124] Among the products produced by catalyzing substrate S1 using the engineered aminotransferase polypeptide disclosed in the present invention, IT1 and IT2, and T1 and T2, are excess products. The structural formulas of T1 and T2, designated L1, are shown below.

[0125] JPEG0007764620000039.jpg59170

[0126] The improved engineered aminotransferase polypeptides described herein are capable of converting S1 to one or more of T1, T2, D1, and D2 in the presence of an amino donor. In some embodiments, the product has a dr value (i.e., [T1 + T2] / [D1 + D2]) of at least 1, 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more.

[0127] In some embodiments, improved engineered aminotransferase polypeptides that can be used in the above methods are selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 1109, 1120, 1130, 1140, 1150, 1160, 1170, 1180, 1190, 1200, 1210, 1220, 1230, 1240, 1250, 1260, 1270, 1280, 1290, 1300, 1310, 1320, 1330, 1340, 1350, 1360, 1370, 1380, 1390, 1400, 1410, 1420, 1430, 1440, 1450, 1460, 1470, 1480, 1490, 1500, 1510, 1520, 15 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158; NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 6 2, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 1 Also included are amino acid sequences that have at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to any of the reference amino acid sequences selected from the following sequences: 24, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158.

[0128] As described herein and verified in the Examples, the present disclosure contemplates suitable reaction conditions that can be used in the methods herein, including, but not limited to, ranges of pH, temperature, buffer, solvent system, substrate loading, polypeptide loading, and reaction time. Additional suitable reaction conditions for carrying out the methods of biocatalytically converting substrate compounds to product compounds using the aminotransferase polypeptides described herein can be readily optimized by routine experimentation. Such routine experimentation may include, but is not limited to, contacting the engineered aminotransferase polypeptide with the substrate compound under experimental reaction conditions of concentration, pH, temperature, and solvent conditions, and detecting the product compound using, for example, the methods described in the Examples provided herein.

[0129] As noted above, engineered polypeptides having aminotransferase activity for use in the disclosed methods are generally selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, , 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158.

[0130] The substrate compound in the reaction mixture can be varied, taking into account, for example, the amount of desired product compound, the effect of substrate concentration on enzyme activity, the stability of the enzyme under the reaction conditions, and the percentage of substrate-to-product conversion. In some embodiments of the method, suitable reaction conditions include a substrate S1 loading of at least about 0.5 g / L, at least about 1 g / L, at least about 5 g / L, at least about 10 g / L, at least about 15 g / L, at least about 20 g / L, at least about 30 g / L, at least about 50 g / L, at least about 75 g / L, at least about 100 g / L, or more. The substrate loading values ​​provided herein are based on the molecular weight of compound A1, although it is contemplated that equimolar amounts of various hydrates and salts of the compound can be used in the method.

[0131] In the methods described herein, the engineered aminotransferase polypeptide catalyzes the formation of a chiral amine product from a ketone substrate and an amino donor. In some embodiments, the amino donor in the reaction conditions includes any suitable amino acid selected from alanine, isopropylamine (also known as 2-aminopropane), phenylalanine, glutamine, leucine, or 3-aminobutyric acid, or any suitable chiral or achiral amine selected from methylbenzylamine. The amino donor may also be used in the form of a salt (e.g., alanine hydrochloride, alanine acetate, isopropylamine hydrochloride, isopropylamine acetate, etc.). In some embodiments, the amino donor is isopropylamine. In some embodiments, suitable reaction conditions include the amino donor, particularly isopropylamine, being present in a loading amount of at least about 1 times the molar loading of substrate S1. In some embodiments, isopropylamine is present in a loading amount of 0.1 M to about 4.0 M.

[0132] In reaction embodiments, reaction conditions may include a suitable pH. As noted above, the desired pH or desired pH range can be maintained by using an acid or base, a suitable buffer, or a combination of a buffer and the addition of an acid or base. The pH of the reaction mixture can be controlled before and / or during the reaction process. In some embodiments, suitable reaction conditions include a solution pH of about 7 to about 11.5. In some embodiments, reaction conditions include a solution pH of about 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, or 11.5.

[0133] In embodiments of the methods herein, appropriate temperatures can be used for the reaction conditions, taking into account, for example, increased reaction rates at higher temperatures and enzyme activity over a sufficiently long reaction time. Thus, in some embodiments, appropriate reaction conditions include temperatures of about 10°C to about 65°C, about 25°C to about 50°C, about 25°C to about 40°C, or about 25°C to about 30°C. In some embodiments, appropriate reaction temperatures include temperatures of about 25°C, 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, or 60°C. In some embodiments, the temperature during the enzymatic reaction can be maintained at a specific temperature throughout the reaction. In some embodiments, the temperature during the enzymatic reaction can be adjusted to match the temperature profile during the reaction.

[0134] Methods using engineered aminotransferases are typically carried out in water or a solvent. Suitable solvents include aqueous buffers, organic solvents, and / or co-solvent systems, which typically include an aqueous solvent and an organic solvent. The aqueous solution (water or aqueous co-solvent system) can be pH buffered or unbuffered. In some embodiments, methods using engineered aminotransferase polypeptides are typically carried out in an aqueous co-solvent system including an organic solvent (e.g., methanol, ethanol, propanol, isopropanol (IPA)), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), isopropyl acetate, ethyl acetate, butyl acetate, 1-octanol, heptane, octane, methyl tert-butyl ether (MTBE), toluene, etc.), an ionic liquid (e.g., 1-ethyl 4-methylimidazole tetrafluoroborate, 1-butyl-3-methylimidazole tetrafluoroborate, 1-butyl-3-methylimidazole hexafluorophosphate, etc.). The organic solvent component in the aqueous co-solvent system can be miscible with the aqueous component to provide a single liquid phase, or partially miscible or immiscible with the aqueous component to provide two liquid phases. Carbon dioxide generated during the hydrolysis reaction can cause foam formation, so an anti-foaming agent can be added as needed. An exemplary aqueous co-solvent system includes water and one or more organic solvents. Typically, the organic solvent component of the aqueous co-solvent system is selected so as not to completely inactivate the aminotransferase. Suitable co-solvent systems can be readily identified by measuring the enzymatic activity of a particular engineered aminotransferase using an enzyme activity assay, such as those described herein, with a defined substrate of interest in the candidate solvent system. In some embodiments of the method, the suitable reaction conditions include an aqueous co-solvent, wherein the aqueous co-solvent comprises a mixture of DMSO and ACN at a concentration of about 1% to about 100% (v / v), about 1% to about 60% (v / v), about 2% to about 60% (v / v), about 5% to about 60% (v / v), about 10% to about 60% (v / v), about 10% to about 50% (v / v), or about 10% to about 40% (v / v).In some embodiments of the method, the suitable reaction conditions include a solvent mixture of DMSO and ACN at a concentration of at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%.

[0135] Suitable reaction conditions can include a combination of reaction parameters that provide for the biocatalytic conversion of a substrate compound to a corresponding product compound. Thus, in some embodiments of the present methods, the combination of reaction parameters includes: (a) a substrate S1 loading of about 10 g / L to 100 g / L, (b) an engineering polypeptide loading of about 1 g / L to 50 g / L, (c) an isopropylamine loading of about 0.1 M to 4.0 M, (d) a pH of about 7.0 to 11.5, (e) a temperature of about 10° C. to 65° C., and (f) a solvent mixture of 1% to 70% DMSO and ACN.

[0136] When carrying out the enzymatic reactions described herein, the engineered polypeptide may be added to the reaction mixture in the form of a partially purified or purified enzyme, a heat-treated enzyme solution, whole cells transformed with a gene encoding the enzyme, and / or a cell extract of such cells, and / or a lysate. Whole cells transformed with a gene encoding the engineered polypeptide, or their cell extracts, their lysates, and isolated enzymes may be used in a variety of forms, including solid (e.g., freeze-dried, spray-dried, etc.) or semi-solid (e.g., crude pastes such as wet cells). Cell extracts or cell lysates may be partially purified by precipitation (e.g., treatments such as ammonium sulfate, polyethyleneimine, heat treatment, etc.), followed by a desalting procedure (e.g., ultrafiltration, dialysis, etc.) before lyophilization. Any enzyme product can be stabilized by cross-linking or immobilization to a solid phase material (e.g., a resin) using known cross-linking agents, such as glutaraldehyde.

[0137] In some embodiments of the enzymatic reactions described herein, the reaction is carried out under suitable reaction conditions as described herein, and the engineering polypeptide is immobilized on a solid support. Solid supports that can be used to immobilize the engineering polypeptide for carrying out the enzymatic reaction include, but are not limited to, microspheres or resins containing epoxy-functionalized polymethacrylate, aminoepoxy-functionalized polymethacrylate, octadecyl-functionalized styrene / DVB copolymer, or octadecyl-functionalized polymethacrylate. Exemplary solid supports include, but are not limited to, chitosan beads, Eupergit C, and SEPABEAD (Mitsubishi), including different types of SEPABEAD: EC-EP, EC-HFA / S, EXA252, EXE119, and EXE120.

[0138] In some embodiments, if the engineered polypeptide can be expressed as a secreted polypeptide, a medium containing the secreted polypeptide can be used in the methods herein. In some embodiments, solid reactants (e.g., enzymes, salts, etc.) may be applied to the reaction in various forms, such as powders (e.g., lyophilized, spray-dried, etc.), solutions, emulsions, suspensions, etc. Reactants can be readily lyophilized or spray-dried using methods and equipment well known to those skilled in the art. For example, a small volume of protein solution can be frozen at -80°C and added to a pre-chilled lyophilization chamber, followed by vacuum application.

[0139] In some embodiments, there are several options for the order or manner in which the reactants are added. The reactants can be added simultaneously to the solvent (e.g., a single-phase solvent, a two-phase aqueous co-solvent system, etc.). Alternatively, some reactants can be added first, with other reactants added in a flow stream or in spaced batches. Various features and embodiments of the present disclosure are illustrated in the following representative examples, which are intended to be illustrative and not limiting. [Brief explanation of the drawings]

[0140] [Figure 1] This is the synthetic route for ubrogepant. [Figure 2] The aminotransferase-catalyzed reaction of the present invention. [Figure 3] This is the basic process of virtual screening. [Figure 4] Distribution of amino acid sites near substrate ST1. DETAILED DESCRIPTION OF THE INVENTION

[0141] Example 1: Stage I Aminotransferase Screening A cell lysate (1 g / L lysozyme, 0.5 g / L PMBS, 0.5 g / L nuclease, dissolved in sodium tetraborate buffer, pH 10.5) was added to a well plate containing wet bacterial cells containing various aminotransferases at 200 μL per well and shaken for 1 hour to disrupt the cells. The lysate was then centrifuged, and the supernatant was transferred to a new deep-well plate to obtain the enzyme solution suitable for the reaction. A 96-well deep-well plate was charged with 40 μL of 20 g / L substrate stock solution in DMSO and 50 μL of the reaction mixture (containing 4 M isopropylamine and 2 g / L PLP dissolved in sodium tetraborate buffer, pH adjusted to 10.5 with concentrated hydrochloric acid at 40 °C). The final concentrations of the reaction components were: 5 g / L substrate, 55% enzyme solution (v / v), 20% DMSO, 0.5 g / L PLP, 1 M isopropylamine, 0.025 M sodium tetraborate buffer, pH 10.5. The well plate was placed in a thermostatic shaker at 45 °C for 24 h. After the reaction, the well plate was removed and heated in a water bath shaker at 70 °C for 1 h. After inactivation, the well plate was diluted to 2.5 g / L with pure acetonitrile in a 1:1 ratio. The sample was then injected and detected. HPLC detection showed that SEQ ID NO:2 showed the best activity and selectivity, with a reaction yield of 29% and a dr value of 0.3 after 24 hours.

[0142] Example 2: Expression of aminotransferase polypeptides A single microbial colony containing E. coli BL21(DE3) carrying the aminotransferase polypeptide expression plasmid was inoculated into a 250 mL Erlenmeyer flask containing 50 mL of LB medium (containing 30 μg / mL chloramphenicol) and grown overnight on a shaker at 30°C. The OD of the culture was 600 When the OD of the medium reached 2, 5% (v / v) of the inoculum was added to 250 mL of TB medium in a 1000 mL Erlenmeyer flask, and the flask was placed in a shaker at 30°C for shaking culture. 600 When the pH reached 0.6, IPTG was added to a final concentration of 1 mM to induce expression of the aminotransferase. After 20 hours of cultivation, the culture was centrifuged (8000 rpm, 10 minutes). After centrifugation, the supernatant was discarded and the cells were collected to obtain wet cells. The wet cells could be used directly to prepare the enzyme solution or stored frozen at -20°C until use.

[0143] Example 3: Testing the Solvent Resistance of EQ ID NO:2 0.5 g of the wet bacterial cells of SEQ ID NO: 2 prepared in Example 2 was weighed, and 5 mL of cell lysis solution (containing 1 g / L lysozyme, 0.5 g / L PMBS, and 0.5 g / L nuclease, dissolved in sodium tetraborate buffer, pH 10.5) was added. The cells were disrupted by shaking for 1 hour to obtain a cell lysate. The cell lysate was then centrifuged, and the supernatant was collected to obtain an enzyme solution. The reactor was opened and heated to 45°C. S1 dissolved in DMSO, methanol, and IPA, respectively, was added to the reaction flask. The reaction mixture (4 M isopropylamine, 2 g / L PLP, dissolved in sodium tetraborate buffer, pH adjusted to 10.5 with concentrated hydrochloric acid at 40°C), sodium tetraborate buffer (pH 10.5), and the enzyme solution of SEQ ID NO:2 were added to the reaction flask. The final reaction mixture consisted of 5 g / L substrate, 20% enzyme solution (v / v), 20% solvent (v / v), 0.5 g / L PLP, 1 M isopropylamine, and 0.025 M sodium tetraborate buffer (pH 10.5). The reaction was then carried out for 24 h with magnetic stirring at 400 rpm. After completion of the reaction, the reactor was heated to 70°C and continued heating for 1 h. 5 mL of pure acetonitrile was then added to inactivate the enzyme, and a sample was collected for HPLC detection. As a result of the detection, the yield after 24 hours of reaction in methanol, DMSO, and isopropanol systems is as follows. JPEG0007764620000040.jpg23170

[0144] Example 4: Expression of mutant enzyme library and preparation of enzyme solution for screening Colonies of the mutant enzyme library were selected from the agar plate and inoculated into a 96-well plate containing LB medium containing chloramphenicol, and cultured overnight at 30°C on a shaker. 600 When the OD of the culture reached 2-3, 20 μL was taken from the 96-well plate and inoculated into a 96-well deep well plate (400 μL TB medium per well) containing TB medium containing chloramphenicol, placed on a shaker, and cultured at 30°C. 600When the pH reached 0.6–0.8, IPTG was added as an inducer to a final concentration of 1 mM, and the mixture was placed on a shaker and allowed to express overnight at 30°C (18–20 h). After expression was complete, the deep-well plate containing the bacterial suspension was centrifuged, the supernatant removed, and the wet bacterial cells were obtained. The wet bacterial cells were then stored in a refrigerator at -20°C for at least 24 hours, after which 200 μL of cell lysis solution (1 g / L lysozyme, 0.5 g / L PMBS, 0.5 g / L nuclease, dissolved in 0.05 M sodium tetraborate buffer, pH 10.5) was added per well to the well plate containing the wet bacterial cells and shaken for 1 hour to disrupt the cells and obtain a lysate. The lysate was then centrifuged, and the supernatant transferred to a new deep-well plate to obtain an enzyme solution suitable for screening reactions.

[0145] Example 5: High-throughput screening of enzymes in Phase II 70 μL of substrate mother solution dissolved in methanol, 40 μL of sodium tetraborate buffer (pH 10.5), and 50 μL of isopropylamine mixture (4 M isopropylamine, 2 g / L PLP dissolved in sodium tetraborate buffer, pH adjusted to 10.5 with concentrated hydrochloric acid at 40 °C) were sequentially added to a deep-well plate, followed by 60 μL of the enzyme solution prepared in Example 4. The final concentrations of the reaction components were 5 g / L substrate, 30% (v / v) enzyme solution, 35% methanol, 0.5 g / L PLP, 1 M isopropylamine, and 0.025 M sodium tetraborate buffer, pH 10.5. The well plate was placed in a thermostatic shaker at 45 °C for 24 h. After the reaction, the well plate was removed and heated in a water bath shaker at 70 °C for 1 h. After inactivation, acetonitrile was added in a 1:1 ratio. The sample was diluted to 2.5 g / L and injected for detection.

[0146] Example 6: DMSO:ACN mixed solvent reaction 0.5 g of the wet bacterial cells of SEQ ID NO: 24 prepared in Example 2 was weighed, and 5 mL of cell lysis solution (containing 1 g / L lysozyme, 0.5 g / L PMBS, and 0.5 g / L nuclease, dissolved in sodium tetraborate buffer, pH 10.5) was added. The mixture was shaken for 1 hour to disrupt the cells, and a cell lysis solution was obtained. The cell lysis solution was then centrifuged, and the supernatant was collected to obtain an enzyme solution. The reactor was opened and preheated to 45°C. S1 dissolved in methanol, DMSO, 80% DMSO:20% ACN, 70% DMSO:30% ACN, 60% DMSO:40% ACN, and 50% DMSO:50% ACN, respectively, a reaction mixture (containing 4 M isopropylamine and 2 g / L PLP, dissolved in sodium tetraborate buffer, and adjusted to pH 10.5 (40°C) with concentrated hydrochloric acid), and the enzyme solution of SEQ ID NO: 24 were added to the reaction flask. The final reaction mixture consisted of 50 g / L substrate, 25% (v / v) enzyme solution of SEQ ID NO: 24, 50% (v / v) solvent, 0.5 g / L PLP, 1 M isopropylamine, and 0.025 M sodium tetraborate buffer, pH 10.5. The reaction was carried out for 24 hours with magnetic stirring at 400 rpm. After the reaction was completed, the reactor was heated to 70°C and continued to be heated for 1 hour. After that, 5 mL of pure acetonitrile was added to inactivate the enzyme, and the samples were taken and subjected to HPLC detection. The results of the detection in various solvent systems after 24 hours of reaction are as shown in the table below. JPEG0007764620000041.jpg35170

[0147] Example 7: High-throughput screening of enzymes in Phase III 70 μL of substrate mother solution dissolved in a 70% DMSO:30% ACN mixed solvent, 40 μL of sodium tetraborate buffer (pH 10.5), 50 μL of an isopropylamine mixed solution (4 M isopropylamine, containing 2 g / L PLP, dissolved in sodium tetraborate buffer and adjusted to pH 10.5 (40°C) with concentrated hydrochloric acid), and 60 μL of the enzyme solution prepared in Example 4 were added to a deep well plate in this order, resulting in a final concentration of each component in the reaction system: 30 g / L substrate, 30% (v / v) enzyme solution, 35% DMSO:15% ACN, 0.5 g / L PLP, 1 M isopropylamine, 0.025 M sodium tetraborate buffer, pH 10.5. The well plate was placed in a 55°C thermostatic shaker and reacted for 24 hours. After the reaction was completed, the well plate was removed and heated in a water bath shaker at 70°C for 1 h, then inactivated by adding acetonitrile in a 1:1 ratio, and the sample was diluted to 5 g / L and injected for detection.

[0148] Example 8: Enzyme thermostability testing Preparation of enzyme mother liquor: 1.5 g of SEQ ID NO: 130 cells were weighed and dissolved in 30 mL of cell lysis solution (1 g / L lysozyme, 0.5 g / L PMBS, 0.5 g / L nuclease, dissolved in sodium tetraborate buffer, pH 10.5), shaken at room temperature for 1 hour, centrifuged, and the supernatant was collected for use.

[0149] Heat treatment of enzyme solution: 3 mL of the supernatant of the prepared enzyme solution was collected and heat-treated in water baths at 45°C, 55°C, and 65°C for 2 hours and 24 hours, respectively.

[0150] Detection of heat-treated enzyme solution activity: The reactor was opened and heated to 45°C. The substrate dissolved in a 70% DMSO:30% ACN mixed solvent, the reaction mixture [containing 4 M isopropylamine and 2 g / L PLP, dissolved in sodium tetraborate buffer, and adjusted to pH 10.5 (40°C) with concentrated hydrochloric acid], and the enzyme solution of SEQ ID NO: 130 heat-treated under each condition were sequentially added to the reaction flask. The final reaction mixture was 50 g / L substrate, 35% DMSO:15% ACN, 1 M isopropylamine, 0.5 g / L PLP, 0.025 M sodium tetraborate buffer, pH 10.5, and 25% (v / v) SEQ ID NO: 130 enzyme solution. The reaction was carried out for 24 hours with magnetic stirring at 400 rpm. After completion of the reaction, the reactor was heated to 70°C and the reaction flask was heated for 1 hour. 5 mL of pure acetonitrile was then added to inactivate the reaction. HPLC detection was performed and the enzyme activity under various heat treatment conditions is shown in the table below. JPEG0007764620000042.jpg41170

[0151] Example 9: Testing the pH tolerance of enzymes The reactor was opened in advance, and the temperature was raised to 55°C. The substrate dissolved in a 70% DMSO:30% ACN mixed solvent, the reaction mixture (4 M isopropylamine, 2 g / L PLP, dissolved in sodium tetraborate buffer, pH adjusted to 10.5 (40°C) with concentrated hydrochloric acid), and the enzyme solution of SEQ ID NO: 130 were added to the reaction flask in this order to obtain a final reaction concentration of 50 g / L substrate, 35% DMSO:15% ACN, 1 M isopropylamine (pH 9.5, 10.5, 11, 11.5), 0.5 g / L PLP, 0.025 M sodium tetraborate buffer (pH 9.5, 10.5, 11, 11.5), and 25% (v / v) SEQ ID NO: 130. The NO:130 enzyme solution was reacted for 24 hours with magnetic stirring at 400 rpm. After the reaction was completed, the reactor was heated to 70°C and the reaction flask was heated for 1 hour. 5 mL of pure acetonitrile was added for inactivation. Samples were collected and subjected to HPLC analysis. The yields at pH 9.5, pH 10.5, pH 11, and pH 11.5 for 24 hours are shown in the table below. JPEG0007764620000043.jpg27170

[0152] Example 10: Optimization of reaction temperature The reactor was opened in advance and heated to 30°C, 45°C, 55°C, and 65°C, respectively. The substrate dissolved in a 70% DMSO:30% ACN mixed solvent, the reaction mixture (4 M isopropylamine, 2 g / L PLP, dissolved in sodium tetraborate buffer, pH adjusted to 10.5 at 40°C with concentrated hydrochloric acid), and the SEQ ID NO:130 enzyme solution were added to the reaction flask in that order to obtain a final reaction concentration of 50 g / L substrate, 35% DMSO:15% ACN mixed solvent, 1 M isopropylamine (pH 10.5), 0.5 g / L PLP, 0.025 M sodium tetraborate buffer (pH 10.5), and 25% (v / v) SEQ ID NO:130 enzyme solution. The reaction was carried out for 24 hours with magnetic stirring at 400 rpm. After completion of the reaction, the reactor was heated to 70°C and the reaction flask was heated for 1 hour, after which 5 mL of pure acetonitrile was added to inactivate the reaction. Samples were collected and subjected to HPLC detection. The yield results at 45°C, 55°C and 65°C for 24 hours are shown in the table below. JPEG0007764620000044.jpg28170

[0153] Example 11: Testing the Solvent Tolerance of Engineered Aminotransferases The reactor was opened in advance and heated to 55°C. The substrate dissolved in methanol, DMSO, isopropanol, and ACN, the reaction mixture (containing 4 M isopropylamine and 2 g / L PLP, dissolved in sodium tetraborate buffer, adjusted to pH 10.5 (40°C) with concentrated hydrochloric acid), and the enzyme solution of SEQ ID NO: 130 were added to the reaction flask in that order to obtain a final reaction concentration of 50 g / L substrate, 20%, 35%, 50%, and 60% methanol, DMSO, isopropanol, ACN, 1 M isopropylamine (pH 10.5), 0.5 g / L PLP, 0.025 M sodium tetraborate buffer (pH 10.5), and 25% (v / v) enzyme solution of SEQ ID NO: 130. The reaction was carried out for 24 hours with magnetic stirring at 400 rpm. After completion of the reaction, the reactor was heated to 70°C. The reaction flask was heated for 1 hour and then inactivated by adding 5 mL of pure acetonitrile. Samples were taken and subjected to HPLC detection, and the results of the yields over 24 hours under various solvent concentrations are shown in the table below. JPEG0007764620000045.jpg53170

[0154] Example 12: All-organic phase reaction The reactor was opened and heated to 55°C. Substrate S1 dissolved in methanol, DMSO, isopropanol, ACN, ethyl acetate, isopropyl acetate, and toluene, respectively, was added to the reaction flask in this order. An isopropylamine mixture (containing 0.25 mL of purified water and 3.5 g / L PLP), and whole cells of SEQ ID NO:130 were added to the reaction flask. The final reaction concentrations were 50 g / L substrate, 86% methanol, DMSO, isopropanol, ACN, ethyl acetate, isopropyl acetate, toluene, 1 M isopropylamine, 0.5 g / L PLP, and 50 g / L whole cells of SEQ ID NO:130. The reaction was carried out for 24 hours with magnetic stirring at 400 rpm. After the reaction was completed, the reactor was heated to 70°C and the reaction flask was heated for 1 hour. Then, 5 mL of pure acetonitrile was added for inactivation. Samples were taken and subjected to HPLC detection. The 24-hour yield results for various solvent concentrations are shown in the table below. JPEG0007764620000046.jpg45170

[0155] Example 13: Fermentation and post-treatment A single colony of E. coli BL21(DE3) containing the desired engineered aminotransferase polypeptide expression plasmid was inoculated into 50 mL of LB broth containing 30 μg / mL chloramphenicol (5.0 g / L Yeast Extract LP0021, 10 g / L Tryptone LP0042, 10 g / L sodium chloride) and cultured at 30°C in a shaker at 250 rpm for 16 h. The OD of the culture was 600 When the OD reached 3.5-4.5, the culture was removed from the shaker and immediately inoculated into a fermenter. A 1.0 L fermenter containing 0.4 L of growth medium was sterilized in a high-pressure steam sterilizer at 121°C for 30 min. The fermenter was inoculated with the culture from the shake flask. The fermenter temperature was maintained at 37°C using a jacket, agitated at 200-800 rpm, and air was supplied to the fermenter at 0.4-0.8 L / min to maintain the dissolved oxygen concentration above 30%. The pH of the culture was maintained at 7.0 by adding 25-28% v / v ammonium hydroxide. Growth was maintained by feeding a feed solution containing 500 g / L food-grade glucose dextrose monohydrate, 12 g / L ammonium chloride, and 5 g / L magnesium sulfate heptahydrate. The OD of the culture was 0.25-0.4 L / min. 600When the pH reached 25 ± 5, the culture temperature was lowered and maintained at 30°C. Aminotransferase expression was induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. Fermentation was continued for approximately 16 h, followed by removal from the tank. The wet cells were collected by centrifugation at 8000 rpm for 10 min at 4°C in a Thermo Multifuge X3R centrifuge. The collected wet cells were either used directly in the next downstream recovery process or frozen and stored at -20°C until use. Six grams of wet cells were resuspended in 30 mL of 100 mM potassium phosphate buffer (pH 7.5) containing 250 μM pyridoxal 5'-phosphate (PLP) at 4°C. The cells were homogenized and triturated twice using a homogenizer at 800 bar to release the aminotransferase from the cells. The resulting lysate was clarified by centrifugation at 8000 rpm for 10 min at 4°C in a Thermo Multifuge X3R centrifuge. The clarified supernatant was dispensed into shallow containers, frozen at -20°C, and lyophilized to an enzyme powder using a freeze dryer. The aminotransferase enzyme powder was stored frozen at -20°C.

[0156] Example 14: Aminotransferase-catalyzed reactions A water bath was started and heated to 55°C. Two 500 mL reaction flasks were fixed on iron stands and placed in the preheated water bath. 20 g of S1, 70 mL of DMSO, and 30 mL of ACN were added to the two 500 mL reaction flasks in this order and stirred to completely dissolve S1. Next, 50 mL of reaction mixture (containing 4 M isopropylamine and 2 g / L PLP, dissolved in sodium tetraborate buffer, and adjusted to pH 10.5 (40°C) with concentrated hydrochloric acid) was added with the enzyme powders of SEQ ID NO: 24 and SEQ ID NO: 130 prepared in Example 13, respectively. The final reaction mixture was 100 g / L S1, 35% DMSO:15% ACN, 1 M isopropylamine (pH 10.5), 0.5 g / L PLP, 0.025 M sodium tetraborate buffer (pH 10.5), 20 g / L SEQ ID NO: 24 or SEQ ID NO: 130 (numbered as Reaction 1 and Reaction 2, respectively). During the reaction process, the pH of the reaction mixture was adjusted with 6 M isopropylamine aqueous solution using a real-time pH controller, and the pH of the reaction mixture was maintained at pH 10.3 to pH 10.5. A 200μL sample was taken at 24h, 48h, 72h, and 96h and heated at 70°C for 1h. 200μL of pure acetonitrile was then added to inactivate the reaction, followed by HPLC detection. The reaction yields are shown in the table below. JPEG0007764620000047.jpg39170

[0157] Example 15: Post-reaction treatment The reaction solution from Example 14 was rotary evaporated at 40°C under -0.095 MPa with a water pump to remove isopropylamine and acetonitrile, and 2 M sodium hydroxide was added to adjust the reaction system to pH 10. The reaction solution was then extracted with 100 mL of ethyl acetate, the supernatant was separated, and the lower aqueous phase was extracted again with 50 mL of ethyl acetate. The combined ethyl acetate layers were washed twice with 50 mL of saturated brine and separated. The ethyl acetate was then removed by rotary evaporation at 40°C under -0.095 MPa with a water pump, and the ethyl acetate was recovered using a condenser. The crude product was then crystallized using a mixed solvent of ethyl acetate / n-heptane (1:2 (v / v)). Final Reaction 1 yielded 13.1 g of pure product, with a total yield of 77.4%, a dr value of 79, and a purity of 98.5%. Reaction 2 gave 14.3 g of pure product, with an overall yield of 84.5%, a dr of over 100 and a purity of over 99%.

Claims

1. 1. An engineered aminotransferase polypeptide, the amino acid sequence of which has 90% or more sequence identity compared to the sequence set forth in SEQ ID NO:2, and which contains amino acid residue differences at one or more residue positions selected from X52Y, X53T, X53K, X53F, X53E, X53H, X115G, X115E, X126L, X146Q, X183A, X183S, X183T, X190L, and X190I, and which converts S1 to IT or L1 with superior catalytic activity, stability, and / or dr value compared to the SEQ ID NO:2 polypeptide, NO: 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 6 0, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106 , 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158.

2. 10. A polypeptide selected from the aminotransferase polypeptides of claim 1, immobilized on a solid material by chemical bonding or physical adsorption methods.

3. A polynucleotide encoding the polypeptide of claim 1.

4. The polynucleotide sequence is selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 4. The polynucleotide of claim 3, wherein the sequence corresponds to 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, or 157.

5. An expression vector comprising the polynucleotide of claim 3.

6. The expression vector of claim 5, which is a plasmid, cosmid, phage or viral vector.

7. A host cell comprising the expression vector of claim 5, wherein the host cell is Escherichia coli.

8. 10. A method for preparing an aminotransferase polypeptide, comprising culturing the host cell of claim 7 and obtaining the aminotransferase polypeptide from the culture.

9. 9. An aminotransferase catalyst selected from the culture of claim 8, host cells or culture medium containing an aminotransferase polypeptide obtained from the culture, or processed products using these, wherein the product is an extract obtained from the transformant cells, an isolated product obtained by isolating or purifying the aminotransferase in the extract, or an immobilized product obtained by immobilizing immobilized transformant cells and the extract or an isolated product of the extract.

10. A method for preparing a compound of formula I, comprising contacting a substrate of formula XI with an engineered polypeptide of claim 1 under suitable reaction conditions. (where R １ , R ２ , R ３ , R ４ , and R ５ The group is an optionally substituted —H, C １ ~C ６ Hydrocarbyl, halogen (e.g., —F, —Cl, —Br, —I), —NO:2, —NO, —SO ２ R' or -SOR', -SR', -NR'R', -OR', -CO ２ R' or -COR', -C(O)NR', ​​-SO ２ NH ２ or -SO NH ２ , -CN, CF ３ and R ６ is C １ ~C ６ Hydrocarbyl, C １ ~C ６ Halogenated hydrocarbons, C １ ~C ６ may be a hydroxy-substituted hydrocarbon, R ７ is C １ ~C ６ Hydrocarbyl, C １ ~C ６ Halogenated hydrocarbons, C １ ~C ６ may be a hydroxy-substituted hydrocarbon, R ８ may be a CBZ protecting group, a BOC protecting group, a Fomc protecting group, a Bn protecting group, or a methoxy(ethoxy)carbonyl protecting group; and each R' is independently H or C. １ C ４ is selected from hydrocarbyl.

11. wherein the product of structural formula I is a mixture of one or more chiral amine products represented by structural formulas II-VI; Due to the activity of the ester group of Compound I, under appropriate reaction conditions, e.g., appropriate temperature, pH, and solvent conditions, a portion of the amine product of Formula I spontaneously undergoes cyclization to form a lactam of Formula VI; 11. The method of claim 10, wherein the chiral amine product of structure VI is a mixture of one or more compounds of the chiral amine products of structures VII-X below:

12. A method for preparing a compound of formula I1, comprising contacting a substrate of formula S1 with an engineered polypeptide of claim 1 under suitable reaction conditions.

13. A method for preparing a compound of formula L1, comprising contacting a substrate of formula S1 with an engineering polypeptide of claim 1 under suitable reaction conditions.

14. 14. The method of claim 13, wherein the product has a dr value (i.e., [T1+T2] / [D1+D2]) of at least 1, 2, 3, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more.

15. The method according to any one of claims 11 to 14, wherein the reaction solvent comprises methanol, dimethyl sulfoxide (DMSO), acetonitrile (ACN), dimethylformamide (DMF), methyl tert-butyl ether (MTBE), isopropyl acetate, ethanol, propanol, isopropanol (IPA), or a mixture of two or more of these solvents.

16. 15. The method of any one of claims 11 to 14, wherein the reaction conditions comprise a temperature of from 10°C to 65°C.

17. 15. The method of any one of claims 11 to 14, wherein the reaction conditions comprise a pH of 7.0 to a pH of 11.

5.

18. 15. The method of any one of claims 11 to 14, wherein the substrate is present at a loading of from 10 g / L to 100 g / L.

Images